4.7 Article

Direct differentiation of bone marrow mononucleated cells into insulin producing cells using pancreatic β-cell-derived components

期刊

SCIENTIFIC REPORTS
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-019-41823-9

关键词

-

资金

  1. Korea Health Technology R&D Project Strategic Center of Cell and Bio Therapy for Heart, Diabetes & Cancer through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare (MHW) [HI17C2085, A120273, A062260]
  2. Ministry of Science, ICT & Future Planning, Republic of Korea [2016R1D1A1B03933437]
  3. National Research Foundation of Korea [2016R1D1A1B03933437] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Transplantation of stem cell-derived insulin producing cells (IPCs) has been proposed as an alternative to islet transplantation for the treatment of diabetes mellitus. However, current IPC differentiation protocols are focused on generating functional cells from the pluripotent stem cells and tend to rely on multistep, long-term exposure to various exogenous factors. In this study, we addressed the observation that under stress, pancreatic beta-cells release essential components that direct the differentiation of the bone marrow nucleated cells (BMNCs) into IPCs. Without any supplementation with known differentiation-inducing factors, IPCs can be generated from BMNCs by in vitro priming for 6 days with conditioned media (CM) from the beta-cells. In vitro primed BMNCs expressed the beta-cell-specific transcription factors, as well as insulin, and improved hyperglycemia and glucose intolerance after transplantation into the streptozotocin-induced diabetic mice. Furthermore, we have found that components of the CM which trigger the differentiation were enclosed by or integrated into micro particles (MPs), rather than being secreted as soluble factors. Identification of these differentiation-directing factors might enable us to develop novel technologies required for the production of clinically applicable IPCs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据